EMCURE Share Price Performance
₹1,713.60
310.20 (22.10%)
4.6% undervalued intrinsic discount
₹1,795.67
Fair Value
Price ₹1,713.60
AnalystConsensusTarget ₹1,795.67
Fair Value₹1,795.67
Share Pricen/a
Analysis Article • May 22
Emcure Pharmaceuticals Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
EMCURE Community Narratives
AN
Fair Value
·Fair Value ₹1.8k 4.6% undervalued intrinsic discount
Expansion In Chronic Therapies And Emerging Markets Will Thrive
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expansion In Chronic Therapies And Emerging Markets Will Thrive
Key Takeaways Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification. Strategic focus on high-margin products, robust R&D, and limited US exposure strengthen profitability, margin stability, and earnings resilience.Read more
AN
₹1.8k
4.6% undervalued intrinsic discount
Fair Value
Revenue
12.61% p.a.
Profit Margin
13.38%
Future PE
28.57x
Price in 2029
₹2.54k
Trending Discussion
Recently Updated Narratives
AN
EMCURE: Governance Meetings And Roche Partnership Will Shape Steady Forward Outlook
Fair Value: ₹1.8k 4.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Emcure Pharmaceuticals Limited Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 48.76
- 60.26%
- 10.04%
- 24.2%
About EMCURE
- Founded
- 1981
- Employees
- 6731
- CEO
- WebsiteView website
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
Recent EMCURE News & Updates
Narrative Update • May 03
